Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)

Market Cap	10.84B +32.9%
Revenue (ttm)	1.62B +13.7%
Net Income	424.54M +24.6%
EPS	1.06 +29.4%
Shares Out	406.18M
PE Ratio	25.10
Forward PE	23.82
Dividend	0.29 (1.09%)
Ex-Dividend Date	Jun 20, 2025

Volume	8,996,600
Average Volume	4,634,472
Open	24.76
Previous Close	25.02
Day's Range	24.76 - 26.98
52-Week Range	18.70 - 35.58
Beta	0.01
RSI	54.79
Earnings Date	Apr 17, 2026

About Aurisco Pharmaceutical

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 1,784
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 605116

Financial Performance

In 2024, Aurisco Pharmaceutical's revenue was 1.48 billion, an increase of 16.89% compared to the previous year's 1.26 billion. Earnings were 354.79 million, an increase of 22.59%.